Navigation Links
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Date:3/18/2009

tion ratio.

"Zoticon is delighted that Sopherion Therapeutics LLC has accomplished its recruitment objectives for the Phase III registration trial in a timely and efficient manner, which can be directly attributed to the strength and quality of its management team," said Asher Nathan, Managing Director of Zoticon and Chairman of the Board of Sopherion Therapeutics LLC.

"Myocet has the potential to be a valued addition to the treatment of metastatic breast cancer," said Ronald H. Goldfarb, Ph.D., President and CEO of Sopherion Therapeutics. "We look forward to reporting the efficacy results from this clinical trial after the required period of follow-up."

About Myocet(TM) (Nonpegylated Liposomal Doxorubicin)

Myocet is a liposome-encapsulated doxorubicin-citrate complex. By encapsulating doxorubicin in a liposome -- a manufactured, microscopic, vesicle consisting of discreet aqueous compartments surrounded by membranes composed of naturally occurring fats -- its distribution in the body is altered in such a way as to reduce doxorubicin's toxicity. Extensive clinical studies of Myocet in women with breast cancer have shown that the cardiac toxicity of doxorubicin can be significantly reduced, while the efficacy of the drug is maintained. This delivery system does not encompass pegylation and yields very little hand foot syndrome

About Sopherion Therapeutics, LLC

Sopherion Therapeutics, LLC is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patients suffering from advanced cancer, particularly in the metastatic stage. Sopherion is dedicated to the acquisition, discovery, development and commercialization of novel anti-cancer therapies with unique therapeutic activities that address unmet medical needs in and extend human life. In 2004, Sopherion en
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... (PRWEB) May 16, 2013 Cambridge Healthtech ... from August 19-23, 2013 at the Renaissance Waterfront Hotel ... Summit provide a close-up look at the current strategies ... ensuring bottom-line quality. Leaders in the field will ... to produce biopharmaceuticals with greater specificity and efficiency. , ...
(Date:5/16/2013)... 16, 2013 Scientists at the Center for ... , and the California -based biopharmaceutical ... novel therapy for reversing memory decline in mice with ... significant cognitive improvement in advanced stage AD mice. The ... reversing cognitive decline for advanced stage AD mice, and ...
(Date:5/16/2013)... , May 16, 2013 /PRNewswire/ ... market research report is available in ... Diagnostic Cardiac Biomarkers for Acute Coronary ... Forecasts http://www.reportlinker.com/p01182969/MediPoint-Diagnostic-Cardiac-Biomarkers-for-Acute-Coronary-Syndromes---APAC-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... for Acute Coronary Syndromes - APAC ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 A number of ... well. According to a report from abcactionnews.com, it was no ... to help, My Cleaning Products recommended to the management and ... Bug Bully. It also encouraged the public to try samples ... , The report dated May 11, 2013 determined that the ...
Breaking Biology Technology:The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 3MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 4MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 5MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 6MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 7MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 8Bed Bugs Plague Tarpon Springs Apartment Complex, Non-Pesticide Bed Bug Spray Recommended to Management by My Cleaning Products to Help 2Bed Bugs Plague Tarpon Springs Apartment Complex, Non-Pesticide Bed Bug Spray Recommended to Management by My Cleaning Products to Help 3
... NEW YORK, June 14, 2011 The global biotechnology industry ... industry achieving aggregate profitability for the second year in a ... has grown increasingly scarce for the vast majority of firms ... that depend on years of funding to support drug development. ...
... 2011 Twenty-two of America,s most promising scientists have ... by The Pew Charitable Trusts.  The 2011 Pew ... Fellows, recipients of the Albert Lasker Medical Research Award ... class of Scholars is related to many human diseases ...
... silicon-based information technology has been brought a step closer ... Engineering at UCL and the London Centre for Nanotechnology. ... Photonics journal, provides the first demonstration of an ... silicon substrate (Si) with a wavelength (1300-nm) suitable for ...
Cached Biology Technology:Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 2Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 3Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 4Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 5Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 622 of America's Most Promising Scientists Selected as 2011 Pew Scholars in the Biomedical Sciences 222 of America's Most Promising Scientists Selected as 2011 Pew Scholars in the Biomedical Sciences 322 of America's Most Promising Scientists Selected as 2011 Pew Scholars in the Biomedical Sciences 4UCL grows first telecommunications wavelength quantum dot laser on a silicon substrate 2UCL grows first telecommunications wavelength quantum dot laser on a silicon substrate 3
(Date:5/16/2013)... Injectable nanoparticles developed at MIT may someday eliminate ... to constantly monitor their blood-sugar levels and inject ... to sense glucose levels in the body and ... thereby replacing the function of pancreatic islet cells, ... diabetes. Ultimately, this type of system could ensure ...
(Date:5/16/2013)... 2013 Integrated Biometrics patented LES (Light ... thin film transistor camera introduces Sherlock, a fingerprint ... in the smallest and lightest form factor available ... Mobile ID FAP 45, Certified scanner is highly ... and weight when compared to optical scanners. ...
(Date:5/16/2013)... entirety of an individual,s DNA is examined to look ... health problems is a massively useful technology for diagnosing ... problems if used incorrectly, say new recommendations from the ... today (16 May 2013) in the European Journal ... genome and on exome* sequencing and analysis are now ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2
... States and Europe has identified more than a dozen genes ... forms of kidney disease. The team, known as the CKDGen ... 65,000 individuals of European descent. Common variations in several genes ... kidney function or chronic kidney disease than in those with ...
... at night disrupts circadian cell division, reveals a new ... University of Haifa-Oranim Department of Environmental and Evolutionary Biology ... of Leicester. "Damage to cell division is characteristic of ... causes of this damage," notes Dr. Ben-Shlomo. The study ...
... than 120 leading researchers from across the molecular,life sciences will ... life sciences conference to be,organized by the European Molecular Biology ... September 2010. Confirmed special lecturers and keynote speakers include: ... telemorase in health & disease, Richard Losick Stochasticity & ...
Cached Biology News:International research team discovers novel genes influencing kidney disease risk 2Call for abstracts and registration the EMBO Meeting 2010 2Call for abstracts and registration the EMBO Meeting 2010 3
Request Info...
Request Info...
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Request Info...
Biology Products: